Piclidenoson Completed Phase 2 Trials for Keratoconjunctivitis Sicca Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00349466Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca